These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 2425955)

  • 1. Resistance to natural killer cell-mediated cytolysis by a pleiotropic drug-resistant human erythroleukemia (K562-R) cell line.
    Yanovich S; Hall RE; Weinert C
    Cancer Res; 1986 Sep; 46(9):4511-5. PubMed ID: 2425955
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The low affinity 40,000 Fc gamma receptor and the transferrin receptor can be alternative or simultaneous target structures on cells sensitive for natural killing.
    Perl A; Looney RJ; Ryan DH; Abraham GN
    J Immunol; 1986 Jun; 136(12):4714-20. PubMed ID: 3011902
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Susceptibility to natural killer cell-mediated cytolysis is independent of the level of target cell class I HLA expression.
    Leiden JM; Karpinski BA; Gottschalk L; Kornbluth J
    J Immunol; 1989 Mar; 142(6):2140-7. PubMed ID: 2493507
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Human tumor cell line resistance to chemotherapeutic agents does not predict resistance to natural killer or lymphokine-activated killer cell-mediated cytolysis.
    Harker WG; Tom C; McGregor JR; Slade L; Samlowski WE
    Cancer Res; 1990 Sep; 50(18):5931-6. PubMed ID: 1975512
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Discordance between transferrin receptor expression and susceptibility to lysis by natural killer cells.
    Bridges KR; Smith BR
    J Clin Invest; 1985 Sep; 76(3):913-8. PubMed ID: 2995450
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of altered membrane fluidity on NK cell-mediated cytotoxicity. I. Selective inhibition of the recognition or post recognition events in the cytolytic pathway of NK cells.
    Roozemond RC; Bonavida B
    J Immunol; 1985 Apr; 134(4):2209-14. PubMed ID: 3855929
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Human leukemia-derived cell lines and clones as models for mechanistic analysis of natural killer cell-mediated cytotoxicity.
    Zarcone D; Tilden AB; Friedman HM; Grossi CE
    Cancer Res; 1987 May; 47(10):2674-82. PubMed ID: 2436754
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Protection against natural killer cells by interferon-gamma treatment of K562 cells cannot be explained by augmented major histocompatibility complex class I expression.
    Nishimura M; Mitsunaga S; Akaza T; Mitomi Y; Tadokoro K; Juji T
    Immunology; 1994 Sep; 83(1):75-80. PubMed ID: 7821970
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Natural cytotoxicity in humans: susceptibility of freshly isolatd tumor cells to lysis.
    Vose BM; Moore M
    J Natl Cancer Inst; 1980 Aug; 65(2):257-63. PubMed ID: 6157044
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Studies on the mechanism of natural killer cell-mediated cytotoxicity. IV. Interferon-induced inhibition of NK target cell susceptibility to lysis is due to a defect in their ability to stimulate release of natural killer cytotoxic factors (NKCF).
    Wright SC; Bonavida B
    J Immunol; 1983 Jun; 130(6):2965-8. PubMed ID: 6189909
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Heterogeneity of human NK cells: comparison of effectors that lyse HSV-1-infected fibroblasts and K562 erythroleukemia targets.
    Fitzgerald PA; Evans R; Kirkpatrick D; Lopez C
    J Immunol; 1983 Apr; 130(4):1663-7. PubMed ID: 6601135
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Characterization of an oxidation-resistant tumor cell line and its sensitivity to immune response and chemotherapy.
    Sauri H; Kim AT; Shau H
    J Surg Res; 1995 May; 58(5):526-35. PubMed ID: 7745966
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Compared mechanisms of tumor cytolysis by human natural killer cells and activated polymorphonuclear leukocytes.
    Abrams SI; Brahmi Z
    J Immunol; 1984 Jun; 132(6):3192-6. PubMed ID: 6327820
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evidence for an early calcium-independent event in the activation of the human natural killer cell cytolytic mechanism.
    Brahmi Z; Bray RA; Abrams SI
    J Immunol; 1985 Dec; 135(6):4108-13. PubMed ID: 3864859
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Human natural killer cell recognition of herpes simplex virus type 1 glycoproteins: specificity analysis with the use of monoclonal antibodies and antigenic variants.
    Bishop GA; Marlin SD; Schwartz SA; Glorioso JC
    J Immunol; 1984 Oct; 133(4):2206-14. PubMed ID: 6206157
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lysis of human cytomegalovirus infected fibroblasts by natural killer cells: demonstration of an interferon-independent component requiring expression of early viral proteins and characterization of effector cells.
    Borysiewicz LK; Rodgers B; Morris S; Graham S; Sissons JG
    J Immunol; 1985 Apr; 134(4):2695-701. PubMed ID: 2579152
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rapid killing of actinomycin D-treated tumor cells by human mononuclear cells. I. Effectors belong to the monocyte-macrophage lineage.
    Colotta F; Peri G; Villa A; Mantovani A
    J Immunol; 1984 Feb; 132(2):936-44. PubMed ID: 6690624
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cytolysis of mammary tumor targets by resting, interleukin-2 stimulated and in vitro cultured peripheral blood lymphocytes from breast cancer patients.
    Brenner BG; McCrea EL; Margolese RG
    Anticancer Res; 1988; 8(4):653-8. PubMed ID: 3263077
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term killing of natural killer-resistant target cells by interferon-alpha-, interferon-gamma-, and interleukin-2-activated natural killer cells.
    Sarzotti M; Klimpel GR; Baron S
    Nat Immun Cell Growth Regul; 1989; 8(2):66-75. PubMed ID: 2503715
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Resistance against natural killer cell cytotoxicity: analysis of mechanisms.
    Hasenkamp J; Borgerding A; Wulf G; Uhrberg M; Jung W; Dingeldein S; Truemper L; Glass B
    Scand J Immunol; 2006 Oct; 64(4):444-9. PubMed ID: 16970688
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.